RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2019 to Q4 2025

Type / Class
Equity / Class A Common Stock
Symbol
RXRX on Nasdaq
Shares outstanding
514,715,255
Price per share
$4.59
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
323,403,945
Total reported value
$1,322,763,240
% of total 13F portfolios
0%
Share change
+11,654,006
Value change
+$22,423,079
Number of holders
327
Price from insider filings
$4.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 7.2% -15% $152,625,941 +$20,329,177 37,316,856 +15% ARK Investment Management LLC 31 Dec 2025
BAILLIE GIFFORD & CO 4.6% $97,239,635 23,774,972 BAILLIE GIFFORD & CO 31 Dec 2025
BlackRock, Inc. 6.1% $134,057,558 23,436,636 BlackRock, Inc. 31 Dec 2024
RA CAPITAL MANAGEMENT, L.P. 2% $44,187,549 7,725,096 RA Capital Management, L.P. 31 Dec 2024
Kim Yohan 5.9% $1,530,100 267,500 Yohan Kim 04 Apr 2025

As of 31 Dec 2025, 327 institutional investors reported holding 323,403,945 shares of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX). This represents 63% of the company’s total 514,715,255 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 9.2% 47,187,759 +19% 0% $192,997,934
BlackRock, Inc. 7.6% 38,866,779 +22% 0% $158,965,127
ARK Investment Management LLC 7.3% 37,316,856 +11% 1% $152,625,940
STATE STREET CORP 4.9% 25,333,888 +39% 0% $103,615,602
BAILLIE GIFFORD & CO 4.6% 23,774,972 -0.85% 0.08% $97,239,635
SOFTBANK GROUP CORP. 2.6% 13,636,515 -7% 0.36% $55,773,346
GEODE CAPITAL MANAGEMENT, LLC 2.1% 10,934,252 +14% 0% $44,731,450
MIC Capital Management UK LLP 1.9% 9,644,032 0% 8.9% $39,444,095
Sumitomo Mitsui Trust Group, Inc. 1.2% 6,221,025 -17% 0.01% $25,443,992
Amova Asset Management Americas, Inc. 1.2% 6,221,025 -17% 0.29% $25,381,782
Data Collective IV GP, LLC 1.2% 5,941,120 0% 42% $24,299,181
NORGES BANK 1.1% 5,739,064 0% $23,472,772
MORGAN STANLEY 1.1% 5,657,577 -22% 0% $23,139,494
Lingotto Investment Management LLP 0.96% 4,931,057 +34% 0.36% $20,168,023
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.85% 4,396,104 -18% 0.02% $17,980,065
CITADEL ADVISORS LLC 0.82% 4,229,999 +214% 0.01% $17,300,696
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.79% 4,075,219 -2.9% 0% $16,667,644
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.78% 3,994,651 +16% 0% $16,338,123
DCVC Opportunity Fund II GP, LLC 0.77% 3,951,141 0% 97% $16,160,167
UBS Group AG 0.72% 3,692,022 -1.6% 0% $15,100,371
NORTHERN TRUST CORP 0.67% 3,439,949 +3.1% 0% $14,069,391
FMR LLC 0.63% 3,241,892 +0.4% 0% $13,259,340
TWO SIGMA INVESTMENTS, LP 0.6% 3,075,123 +25% 0.02% $12,577,253
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 0.47% 2,404,118 +35% 0.68% $9,832,843
FIRST TRUST ADVISORS LP 0.44% 2,266,691 +26% 0.01% $9,270,766

Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock (RXRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 323,403,945 $1,322,763,240 +$22,423,079 $4.09 327
2025 Q3 324,201,062 $1,582,004,004 +$66,840,758 $4.88 322
2025 Q2 310,182,949 $1,569,493,304 +$26,510,398 $5.06 329
2025 Q1 304,244,163 $1,609,644,830 -$29,277,099 $5.29 330
2024 Q4 304,544,141 $2,058,776,356 +$268,240,445 $6.76 310
2024 Q3 264,392,743 $1,743,289,324 +$54,064,157 $6.59 262
2024 Q2 251,836,128 $1,888,574,788 +$298,622,706 $7.50 264
2024 Q1 212,714,397 $2,120,552,518 +$62,304,334 $9.97 242
2023 Q4 206,501,532 $2,035,976,922 +$306,507,294 $9.86 194
2023 Q3 152,228,034 $1,164,429,792 +$189,175,887 $7.65 189
2023 Q2 127,547,789 $952,749,699 +$12,757,431 $7.47 155
2023 Q1 126,153,704 $841,388,403 +$14,595,249 $6.67 157
2022 Q4 123,786,379 $954,397,559 +$134,707,594 $7.71 144
2022 Q3 113,749,582 $1,210,251,991 +$75,709,491 $10.64 141
2022 Q2 106,463,853 $861,094,172 +$96,496,440 $8.14 130
2022 Q1 95,043,699 $680,250,380 -$12,978,444 $7.16 124
2021 Q4 94,346,907 $1,616,473,942 +$295,962,917 $17.13 122
2021 Q3 54,909,739 $1,262,978,377 +$181,552,159 $23.01 82
2021 Q2 46,974,230 $1,714,334,294 +$1,714,333,294 $36.50 75
2021 Q1 30 $1,000 $33.33 1
2020 Q4 30 $1,000 $33.33 1
2020 Q3 30 $1,000 $33.33 1
2020 Q2 30 $1,000 $33.33 1
2020 Q1 30 $1,000 $33.33 1
2019 Q4 30 $1,000 $33.33 1
2019 Q3 30 $1,000 $33.33 1
2019 Q2 30 $1,000 $33.33 1
2019 Q1 30 $1,000 $33.33 1